Home | Privacy | Contact    

Information About Hepatocellular Carcinoma


Hepatocellular carcinoma - Wikipedia, the free encyclopedia
http://en.wikipedia.org/wiki/Hepatocellular_carcinoma Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the most common type of liver cancer. Most cases of HCC are secondary to either a viral hepatitis ... more...
Hepatocellular Carcinoma
http://emedicine.medscape.com/article/197319-overview Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. Hepatocellular carcinoma is now the third leading cause of cancer deaths worldwide ... more...
Hepatocellular carcinoma: MedlinePlus Medical Encyclopedia
http://www.nlm.nih.gov/medlineplus/ency/article/000280.htm Hepatocellular carcinoma is cancer of the liver. Causes Hepatocellular carcinoma accounts for most liver cancers. This type of cancer occurs more often in men than ... more...
Hepatocellular Carcinoma Causes, Symptoms, Tests, Treatment ...
http://www.hepatocellularcarcinoma.net/ Hepatocellular Carcinoma Causes, Symptoms, Tests, Treatment, Prognosis, Complications and Prevention. Read the complete information here. more...
Hepatocellular carcinoma - PubMed Health - National Center for ...
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001325/ Hepatocellular carcinoma is cancer of the liver. ... Expert-reviewed information summary about the treatment of adult primary liver cancer. more...



Hepatocellular Carcinoma News


hepatocellular carcinoma - Bing News
IMPORTANT: Bing News RSS feed has moved!
Go to the new RSS page and renew your subscription.
read more...
ArQule to present positive tivantinib Phase 2 clinical data for
ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single ... read more...
Phase 2 Trial Update of Tivantinib for
ArQule and Daiichi Sankyo announced Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in read more...
ArQule presents positive Phase 2 data for tivantinib in
ArQule and Daiichi Sankyo, Co. will present Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in read more...
Genetic Risk of
Backgroud and Aim: Chronic hepatitis C virus (HCV) infection is a well known risk factor for read more...